Twist Bioscience Corp (NASDAQ:TWST) President and Chief Operating Officer Patrick John Finn sold company shares on April 2, 2024, in a transaction that amounted to over $16,000. The shares were sold at a price of $32.736 each, according to the latest filing with the Securities and Exchange Commission.
The transaction involved the sale of 492 shares of common stock, which were required to be sold by Finn to cover tax withholding obligations associated with the vesting of Restricted Stock Units. This sale is part of a "sell to cover" transaction mandated by Twist Bioscience's equity incentive plans and is not considered a discretionary trade by Finn.
Following this transaction, Finn's ownership in the company stands at 178,380 shares of common stock. It's worth noting that his remaining shareholdings include shares acquired under the company's Employee Stock Purchase Plan, which are exempt transactions under certain SEC rules.
Twist Bioscience Corp, based in South San Francisco, California, operates in the field of synthetic biology and is known for its innovative work in DNA synthesis.
Investors often monitor the buying and selling activities of company executives as they can provide insights into an insider's view of the company's value. The disclosed transaction provides current and potential investors with up-to-date information on the executive's stake in the company.
InvestingPro Insights
As Twist Bioscience Corp (NASDAQ:TWST) sees its President and Chief Operating Officer adjust his holdings, investors may be looking for context around the company's financial health and market performance. According to InvestingPro data, Twist Bioscience has a market capitalization of approximately $1.85 billion and a notable Price/Book ratio of 3.15 as of the last twelve months leading up to Q1 2024. This suggests that the company's assets are valued relatively high compared to its equity, which is common in growth-oriented companies in the biotech sector.
Despite the company's impressive revenue growth of 21.58% over the last twelve months, analysts contributing to InvestingPro have flagged several points for investors to consider. The company's stock price has experienced significant volatility, and the P/E ratio stands at -8.98, reflecting market expectations of future earnings or a potential overvaluation. Additionally, Twist Bioscience has not been profitable over the last twelve months, with an Operating Income Margin of -79.5%. This could be a concern for investors looking for current profitability rather than long-term growth potential.
On a more positive note, the company holds more cash than debt on its balance sheet and has liquid assets that exceed short-term obligations, which is an InvestingPro Tip indicating financial stability. Another InvestingPro Tip is the stock's large price uptick over the last six months, showing a 78.38% total return, which may appeal to momentum investors.
For those interested in a deeper dive into Twist Bioscience's financials and market performance, InvestingPro offers additional insights and tips. There are 7 more InvestingPro Tips available for TWST at InvestingPro. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, enriching your investment strategy with real-time data and expert analysis.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.